Noida-based National Institute of Biologicals (NIB), an apex autonomous institute under the Union health ministry, shall function as an additional facility for testing of COVID-19 vaccines, according to a gazette notification issued on Tuesday.
At present, all types of vaccines are being tested for lot release purposes at the Central Drugs Laboratory (CDL),Kasauli.
The aim is to expedite the testing process of COVID-19 vaccines as and when they become available to ensure their supply does not get affected, an official said.
The NIB is performing primary statutory function of quality control of biologicals such as insulin, blood products and diagnostic kits among others.
The notification issued by the health ministry stated that making available suitable COVID-19 vaccines is essential to meet the requirements of emergency arising due to the pandemic and therefore, in public interest, it is necessary and expedient to regulate the testing of vaccine for prevention and management of the infection.
"Whereas, the central government, in consultation with the Drugs Controller (India), is of the considered view that the supply of COVID-19 vaccine must not get affected and the vaccine must remain available to the public.
"Now, therefore, in exercise of the powers conferred by sections 6 and 26B read with section 33P of the Drugs and Cosmetics Act, 1940 and rule 3 of the Drugs and Cosmetics Rules, 1945, the Central Government, hereby directs that the National Institute of Biologicals, Noida, in addition to its existing functions shall perform the function of Central Drugs Laboratory as an additional facility in respect of COVID-19 vaccine," the notification read.
In case of any inconsistency between this notification and any rule made under the said Act, the provisions of this notification shall prevail over such rule in public interest so as to meet the requirements of emergency which have arisen due to COVID-19 pandemic, the notification stated.
The notification shall remain into force for a period up to November 30, 2021.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU